Gilbert Wagener
Technik-/Wissenschafts-/F&E-Leiter bei PHARNEXT SCA
Profil
Gilbert Wagener is currently the Chief Medical Officer at Pharnext SA since 2023.
Prior to this, he held the same position at Cell2B - Advanced Therapeutics SA and Ixaka Ltd.
Dr. Wagener holds a doctorate from Erasmus University Rotterdam and Philipps University of Marburg, and an MBA from the University of Basel.
Aktive Positionen von Gilbert Wagener
| Unternehmen | Position | Beginn |
|---|---|---|
| PHARNEXT SCA | Technik-/Wissenschafts-/F&E-Leiter | 15.06.2023 |
Ehemalige bekannte Positionen von Gilbert Wagener
| Unternehmen | Position | Ende |
|---|---|---|
Ixaka Ltd.
 Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | - |
Cell2B - Advanced Therapeutics SA
 Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Cell2B - Advanced Therapeutics SA engages in the development of stem cell therapies for immune and inflammatory diseases. Its pipeline consists of cord blood unit expansion and anti-rejection medications. The company was founded by Daniela Couto, David Braga Malta, Francisco dos Santos, and Pedro Andrade in 2011 and is headquartered in Cantanhede, Portugal. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Gilbert Wagener
| Philipps University of Marburg | Doctorate Degree |
| University of Basel | Masters Business Admin |
| Erasmus University Rotterdam | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PHARNEXT SCA | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Cell2B - Advanced Therapeutics SA engages in the development of stem cell therapies for immune and inflammatory diseases. Its pipeline consists of cord blood unit expansion and anti-rejection medications. The company was founded by Daniela Couto, David Braga Malta, Francisco dos Santos, and Pedro Andrade in 2011 and is headquartered in Cantanhede, Portugal. | Health Technology |
Ixaka Ltd.
Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
